AVEO Oncology (AVEO) discloses CHMP regulatory action may be considered if August 2019 interim OS analysis confirms negative trend
AVEO Oncology (NASDAQ: AVEO) disclosed in an SEC filing:In August 2017, the European Commission granted marketing authorization for tivozanib to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)